Print ISSN:-2394-2789

Online ISSN:-2394-2797


Current Issue

Year 2020

Volume: 7 , Issue: 1

Article Access statistics

Viewed: 625

Emailed: 0

PDF Downloaded: 192

International Journal of Pharmaceutical Chemistry and Analysis

Targeting cyclin dependent kinases in management of human cancer

Full Text PDF Share on Facebook Share on Twitter

Author Details : Jimishaben D. Kher, Jagat Upadhyay

Volume : 3, Issue : 4, Year : 2016

Article Page : 193-197

Suggest article by email


Uncontrolled proliferation is the hall mark of cancer and abnormal cell cycle regulation in cancer. CDK plays very important role in the control of the cell cycle and its proliferation. CDK2 is the “superstar” among the CDK family.CDK2 has cyclin A and cyclin E in its complex which the cyclin A complex require to progress through S phase regulated by phosphorylation and cyclin E require to transition from the G1 to S phase in cell cycle. Also, the mechanism of binding of CDK2 with its inhibitors as well as the changes of binding mechanisms following conformational variation of CDK2 are compared. Considering this fact, inhibition or disruption of the CDK2/cyclin complexes should be possible to suppress the hyper activation of CDK2 and hold back the infinite cell proliferation. There are main four binding site of CDK inhibitors. Competitive binding sites (site 1), Noncompetitive binding sites (site 2 and 3), Allosteric binding site (site 4). CDK inhibitors are mainly used in cancers including leukemia, melanoma, solid tumors and other types are being targeted.

Cancer, CDK, CDK2, CDK2 Inhibitors

How to cite : Kher J D, Upadhyay J, Targeting cyclin dependent kinases in management of human cancer. Int J Pharm Chem Anal 2016;3(4):193-197

Copyright © 2016 by author(s) and Int J Pharm Chem Anal. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (